PPAR
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S2871 | T0070907 | <1 mg/mL | 26 mg/mL | <1 mg/mL |
| S7767 | AZ6102 | <1 mg/mL | 85 mg/mL | <1 mg/mL |
| S7484 | FH535 | <1 mg/mL | 72 mg/mL | <1 mg/mL |
| S4527 | Fenofibric acid | 63 mg/mL | 63 mg/mL | 63 mg/mL |
| S8029 | WY-14643 (Pirinixic Acid) | <1 mg/mL | 64 mg/mL | 52 mg/mL |
| S1729 | Gemfibrozil | <1 mg/mL | 50 mg/mL | 50 mg/mL |
| S4708 | Palmitoylethanolamide | <1 mg/mL | 59 mg/mL | 59 mg/mL |
| S2915 | GW9662 | <1 mg/mL | 55 mg/mL | <1 mg/mL |
| S8025 | GSK3787 | <1 mg/mL | 79 mg/mL | <1 mg/mL |
| S2505 | Rosiglitazone maleate | <1 mg/mL | 94 mg/mL | <1 mg/mL |
| S2556 | Rosiglitazone | <1 mg/mL | 71 mg/mL | <1 mg/mL |
| S2590 | Pioglitazone | <1 mg/mL | 10 mg/mL | <1 mg/mL |
| S5615 | GW501516 | -1 mg/mL | 90 mg/mL | -1 mg/mL |
| S3878 | Bavachinin | -1 mg/mL | 67 mg/mL | -1 mg/mL |
| S3786 | Glabridin | -1 mg/mL | 64 mg/mL | -1 mg/mL |
| S3720 | Elafibranor | <1 mg/mL | 76 mg/mL | 76 mg/mL |
| S8020 | GW0742 | <1 mg/mL | 94 mg/mL | 44 mg/mL |
| S2665 | Ciprofibrate | <1 mg/mL | 58 mg/mL | 58 mg/mL |
| S4159 | Bezafibrate | <1 mg/mL | 72 mg/mL | 18 mg/mL |
| S4207 | Clofibric Acid | <1 mg/mL | 43 mg/mL | 43 mg/mL |
| S1794 | Fenofibrate | <1 mg/mL | 72 mg/mL | 46 mg/mL |
| S2075 | Rosiglitazone HCl | <1 mg/mL | 79 mg/mL | 79 mg/mL |
| S8432 | Troglitazone (CS-045) | <1 mg/mL | 88 mg/mL | 15 mg/mL |
| S2871 | T0070907 | <1 mg/mL | 26 mg/mL | <1 mg/mL |
| S7767 | AZ6102 | <1 mg/mL | 85 mg/mL | <1 mg/mL |
| S7484 | FH535 | <1 mg/mL | 72 mg/mL | <1 mg/mL |
| S4527 | Fenofibric acid | 63 mg/mL | 63 mg/mL | 63 mg/mL |
Isoform-specific Inhibitors
- PPAR Inhibitors (28)
- New PPAR Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2871 |
T0070907T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. |
PPARγ mRNA expression and activated PPARγ in nuclear extraction in monocytes after treatment with 10 μM atorvastatin for 24 h in the presence or absence of T0070907 (10 nM) or rosiglitazone (100 nM).§P<0.05 for atorvastatin versus vehicle. *P<0.05 for atorvastatin plus the indicated chemicals versus atorvastatin.
|
|
| S7767 |
AZ6102AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells. |
||
| S7484 |
FH535FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist. |
BrdU assay was used to detect the proliferation level of cells in four groups: the control group, FH535 (15 μM) group, NAM (50 mM) + FH535 (15 μM) group, REV (100 μM) + FH535 (15 μM) group. A. At the next day, the cells were fixed and immunostained for BrdU (red) and with DAPI (blue) then merged the two pictures of the same field. The scale bar is 100 μm. B. The total numbers of cells (DAPI-staining cells) per field in the four groups. C. BrdU-positive rate of C2C12 cells was analyzed. Each value represents the mean ± standard error of the mean of triplicate determinations from three independent cell preparations. *P<0.05, **P<0.01, ***P<0.001 vs the value of the control; n=3; error bars ± standard error of means. Statistical analysis was conducted using one-way ANOVA. Original magnification is ×200.
|
|
| S4527 |
Fenofibric acidFenofibric acid is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides. |
||
| S5121New |
PhytolPhytol, a diterpene alcohol from chlorophyll widely used as a food additive and in medicinal fields, shows antinociceptive and antioxidant activities as well as anti-inflammatory and antiallergic effects. It is a specific activator of PPARα. |
||
| S8029 |
WY-14643 (Pirinixic Acid)WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM. |
(A) Acot1 mRNA following adenovirus treatments and 0.1% Wy-14643 supplementation (n=7-9). (B) H&E staining shows that Wy-14643 reduced and normalized lipid droplet accumulation in the Acot1 knockdown treatment group.
|
|
| S1729 |
GemfibrozilGemfibrozil is an activator of peroxisome proliferator-activated receptor-alpha (PPARα), used for the treatment of hypercholesterolemia and hypertriglyceridemia. |
||
| S4708 |
PalmitoylethanolamidePalmitoylethanolamide(PEA) is an endogenous fatty acid amide and selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM. |
||
| S2915 |
GW9662GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM in a cell-free assay, with at least 10- to 600-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ. |
Quantitative PCR analysis of Ucp1 expression in the adipocytes treated with (f) inhibitors of B-Raf (B-Rafi) and RAC1 (Rac1i). (c) Representative western blot analysis of ERK, P38, and AKT pathways in primary inguinal adipocytes.
|
|
| S8025 |
GSK3787GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ. |
PPARβ/δ activation protects against corticosterone-induced astrocyte damage. (a) Astrocytes treated with Cort at concentrations of 1, 10, and 100 μM( n = 4; F = 329.412 > F0.01 (3, 12); **P < 0.01 vs. Con group); (b) MTT assay performed 24 hours after treatment with Cort (10 μM) and GW (0.1, 1, and 10 μM) (n = 5; F = 7.402 > F 0.01 (4, 20); **P < 0.01 vs. Con group; #P < 0.05 vs. Cort. group); (c) MTT assay performed after 24 hours of treatment with Cort (10 μM), GW (10 μM), and GSK (10 μM) (n = 4; F = 42.431 > F0.01 (3, 12); **P < 0.01 vs. Con group; ##P < 0.01 vs. Cort group; ††P < 0.01 vs. GW group); (d) MTT assay performed 24 hours after treatment with GSK (0.1, 1, and 10 μM) (n = 4; F = 1.659 < F0.01 (3, 12); P > 0.05 vs. Con group); (e) PPARβ/δ expression levels measured by RT-qPCR (n = 4; F = 27.018 > F0.01 (3, 12); **P < 0.01 vs. Con group; #P < 0.05 vs. Cort group; †P < 0.05 vs. GW group); (f) PPARβ/δ expression levels measured by Western blot (n = 4; F = 34.723 > F0.01 (3, 12); **P < 0.01vs. Con group; ##P < 0.01 vs. Cort group; †P < 0.05 vs. GW group). Groups were compared using 1-way ANOVA with post hoc Tukey’s multiple comparisons test. Each data point represents the mean ± SEM. Con, Control; Cort, Corticosterone; GW, GW0742; GSK, GSK3787.
|
|
| S2505 |
Rosiglitazone maleateRosiglitazone, a member of the thiazolidinedione class of antihyperglycaemic agents, is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ with IC50 of 42 nM. |
Total and phosphorylated Akt were detected by western blot in protein lysates of liver, inguinal WAT and gastrocnemius muscle from mice that were treated with an insulin bolus after an overnight fast. |
|
| S2556 |
RosiglitazoneRosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively. Rosiglitazone is a pure ligand of PPAR-gamma, and has no PPAR-alpha-binding action. |
|
|
| S2590 |
PioglitazonePioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, used to treat diabetes; A weak activator for full-length hPPARα, but not full-length hPPARδ. |
PPARγ activation, but not PPARα activation, increases β-klotho expression and FGF21 signaling. Protein (A) levels of β-klotho in hepatocytes after stimulation with or without 20μM Wy14643/Pioglitazone/Rosiglitazone for 24h |
|
| S5615New |
GW501516GW501516 is a synthetic PPARδ-specific agonist that displays high affinity for PPARδ (Ki=1.1 nM) with > 1000 fold selectivity over PPARα and PPARγ. |
||
| S3878New |
BavachininBavachinin is a novel natural pan-PPAR agonist from the fruit of the traditional Chinese glucose-lowering herb malaytea scurfpea. It shows stronger activities with PPAR-γ than with PPAR-α and PPAR-β/δ (EC50 = 0.74 μmol/l, 4.00 μmol/l and 8.07 μmol/l in 293T cells, respectively). |
||
| S3786New |
GlabridinGlabridin, one of the active phytochemicals in licorice extract, binds to and activates the ligand binding domain of PPARγ, as well as the full length receptor. It is also a GABAA receptor positive modulator promoting fatty acid oxidation and improving learning and memory. |
||
| S3720New |
ElafibranorElafibranor is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. |
||
| S8020 |
GW0742GW0742 is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. |
(b) Western blotting used to analyze the expression of caspase-12. The caspase-12 levels were quantified and normalized to the GAPDH levels (n=6; F=23.785>F0.01(3, 20); ∗∗P < 0.01 vs. Con group; ##P < 0.01 vs. Cort group; ††P < 0.01 vs. GW group); (c) Western blotting used to analyze the ratio of cleaved caspase-3 to caspase-3 of the different groups (n=4; F=10.419>F0.01(3, 12); ∗∗P < 0.01 vs. Con group; #P < 0.05 vs. Cort group; †P < 0.05 vs. GW group). Groups were compared using 1-way ANOVA with post hoc Tukey's multiple comparisons test. The data are presented as the mean ± SEM. Con, Control; Cort, Corticosterone; GW, GW0742; GSK, GSK3787
|
|
| S2665 |
CiprofibrateCiprofibrate is a peroxisome proliferator-activated receptor agonist. |
||
| S4159 |
BezafibrateBezafibrate is the first clinically tested dual and pan-PPAR co-agonism. |
||
| S4207 |
Clofibric AcidClofibric acid is a PPARα agonist and hypolipidemic agent. |
||
| S1794 |
FenofibrateFenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative. |
E. The mTOR-lipin1-SREBP1 pathway in the liver of the Rab8af/f and Rab8a-mKO female mice gavaged with fenofibrate (25 mg/kg) or vehicle (H2O) for 8 days. F. mRNA expression of key genes in lipid metabolism in the liver of the Rab8af/f and Rab8a-mKO female mice gavaged with fenofibrate or vehicle for 8 days. n = 4-6. Statistical analyses were carried out using two-way ANOVA. * indicates p <0.05. n.s., not significant.
|
|
| S2075 |
Rosiglitazone HClRosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells. |
|
|
| S8432 |
Troglitazone (CS-045)Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. |
||
| S2871 |
T0070907T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. |
PPARγ mRNA expression and activated PPARγ in nuclear extraction in monocytes after treatment with 10 μM atorvastatin for 24 h in the presence or absence of T0070907 (10 nM) or rosiglitazone (100 nM).§P<0.05 for atorvastatin versus vehicle. *P<0.05 for atorvastatin plus the indicated chemicals versus atorvastatin.
|
|
| S7767 |
AZ6102AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows IC50 of 5 nM for Wnt pathway inhibition in DLD-1 cells. |
||
| S7484 |
FH535FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist. |
BrdU assay was used to detect the proliferation level of cells in four groups: the control group, FH535 (15 μM) group, NAM (50 mM) + FH535 (15 μM) group, REV (100 μM) + FH535 (15 μM) group. A. At the next day, the cells were fixed and immunostained for BrdU (red) and with DAPI (blue) then merged the two pictures of the same field. The scale bar is 100 μm. B. The total numbers of cells (DAPI-staining cells) per field in the four groups. C. BrdU-positive rate of C2C12 cells was analyzed. Each value represents the mean ± standard error of the mean of triplicate determinations from three independent cell preparations. *P<0.05, **P<0.01, ***P<0.001 vs the value of the control; n=3; error bars ± standard error of means. Statistical analysis was conducted using one-way ANOVA. Original magnification is ×200.
|
|
| S4527 |
Fenofibric acidFenofibric acid is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides. |
-Lapatinib-Sorafenib-Imatinib-(STI571)-Drug-Metab-Dispos-20150727.gif)
